Effect of sevoflurane on grafted kidney function in renal transplantation

Jin Ha Park, Jae Hoon Lee, Dong Jin Joo, Ki Jun Song, Yu Seun Kim, Bon-Nyeo Koo, Jin Ha Park, Jae Hoon Lee, Dong Jin Joo, Ki Jun Song, Yu Seun Kim, Bon-Nyeo Koo

Abstract

Background: The objective of this retrospective study was to determine if there are any differences in grafted kidney function in recipients of kidney transplantation (KT) when donors and recipients were anesthetized with sevoflurane compared to desflurane.

Methods: Seventy-three pairs of donors-recipients were anesthetized with sevoflurane (Sevo group) and 71 pairs were anesthetized with desflurane (Des group). We retrospectively investigated the blood urea nitrogen (BUN) levels, creatinine (Cr) levels, and estimated glomerular filtration rates (eGFR) of the recipients in both groups for 1 year postoperatively. We tested non-inferiority for serum creatinine at discharge and 1 year after KT. Short-term (1 year) outcomes of KT were assessed by the incidence of delayed graft function (DGF), acute rejection episodes (ARE), and graft failure.

Results: There were no differences in BUN, Cr, eGFR, or outcomes of KT at 1 year postoperatively. Specifically, the 95% confidence interval for the difference in creatinine levels between the Sevo and Des groups was less than the margin of equivalence at the time of discharge and 1 year after surgery. The occurrences of DGF, ARE, and graft failure were comparable between the groups.

Conclusions: Compared to desflurane, sevoflurane had no adverse effects on grafted renal function or on the short-term outcome of renal transplantation.

Keywords: Creatinine; Glomerular filtration rate; Kidney transplantation; Sevoflurane.

Figures

Fig. 1
Fig. 1
Flowchart of data acquisition. Of the patients who underwent kidney transplantation from a living donor from January 2006 to June 2009, this study included donor-recipient pairs in which the recipient had been anesthetized with the same volatile anesthetic as the donor. We excluded the pairs in which isoflurane was used because of the small sample size. Finally, the enrolled pairs were divided into groups, the sevoflurane group (n = 73, Sevo group) and the desflurane group (n = 71, Des group). IMR, incomplete medical record; UHE, unstable hemodynamic event during transplantation.
Fig. 2
Fig. 2
Transplanted renal function in the immediate postoperative period. Changes in serum blood urea nitrogen (BUN), creatinine (Cr) level, estimated glomerular filtration rate (eGFR), and urine output in the Des group (□) and in the Sevo group (•) during the immediate postoperative period. The changes in the serum concentrations of BUN, Cr, eGFR, and urine output of the recipients during the immediate postoperative period were comparable between the two groups.

References

    1. Holaday DA, Smith FR. Clinical characteristics and biotransformation of sevoflurane in healthy human volunteers. Anesthesiology. 1981;54:100–106.
    1. Gonsowski CT, Laster MJ, Eger EI, 2nd, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiology. 1994;80:556–565.
    1. Gentz BA, Malan TP., Jr Renal toxicity with sevoflurane: a storm in a teacup? Drugs. 2001;61:2155–2162.
    1. Higuchi H, Sumikura H, Sumita S, Arimura S, Takamatsu F, Kanno M, et al. Renal function in patients with high serum fluoride concentrations after prolonged sevoflurane anesthesia. Anesthesiology. 1995;83:449–458.
    1. Eger EI, 2nd, Koblin DD, Bowland T, Ionescu P, Laster MJ, Fang Z, et al. Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg. 1997;84:160–168.
    1. Eger EI, 2nd, Gong D, Koblin DD, Bowland T, Ionescu P, Laster MJ, et al. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg. 1997;85:1154–1163.
    1. Goldberg ME, Cantillo J, Gratz I, Deal E, Vekeman D, McDougall R, et al. Dose of compound A, not sevoflurane, determines changes in the biochemical markers of renal injury in healthy volunteers. Anesth Analg. 1999;88:437–445.
    1. Higuchi H, Sumita S, Wada H, Ura T, Ikemoto T, Nakai T, et al. Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity. Anesthesiology. 1998;89:307–322.
    1. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004;364:1814–1827.
    1. Kosieradzki M, Rowinski W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc. 2008;40:3279–3288.
    1. Artru AA. Renal effects of sevoflurane during conditions of possible increased risk. J Clin Anesth. 1998;10:531–538.
    1. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008;109:c182–c187.
    1. Teixeira S, Costa G, Costa F, da Silva Viana J, Mota A. Sevoflurane versus isoflurane: does it matter in renal transplantation? Transplant Proc. 2007;39:2486–2488.
    1. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study of dose response in man. JAMA. 1973;225:1611–1616.
    1. Cousins MJ, Mazze RI, Kosek JC, Hitt BA, Love FV. The etiology of methoxyflurane nephrotoxicity. J Pharmacol Exp Ther. 1974;190:530–541.
    1. Conzen PF, Kharasch ED, Czerner SF, Artru AA, Reichle FM, Michalowski P, et al. Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. Anesthesiology. 2002;97:578–584.
    1. Conzen PF, Nuscheler M, Melotte A, Verhaegen M, Leupolt T, Van Aken H, et al. Renal function and serum fluoride concentrations in patients with stable renal insufficiency after anesthesia with sevoflurane or enflurane. Anesth Analg. 1995;81:569–575.
    1. Yabu JM, Vincenti F. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis. 2009;16:226–233.
    1. Lee HT, Ota-Setlik A, Fu Y, Nasr SH, Emala CW. Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology. 2004;101:1313–1324.
    1. Hashiguchi H, Morooka H, Miyoshi H, Matsumoto M, Koji T, Sumikawa K. Isoflurane protects renal function against ischemia and reperfusion through inhibition of protein kinases, JNK and ERK. Anesth Analg. 2005;101:1584–1589.
    1. Obal D, Rascher K, Favoccia C, Dettwiler S, Schlack W. Post-conditioning by a short administration of desflurane reduced renal reperfusion injury after differing of ischaemia times in rats. Br J Anaesth. 2006;97:783–791.
    1. Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology. 2003;98:1315–1327.
    1. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1012–1024.
    1. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6:1639–1645.
    1. Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol. 2010;21:189–197.
    1. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Salmela KT. Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int. 2011;79:89–98.
    1. Lebkowska U, Malyszko J, Lebkowska A, Koc-Zorawska E, Lebkowski W, Malyszko JS, et al. Neutrophil gelatinase-associated lipocalin and cystatin C could predict renal outcome in patients undergoing kidney allograft transplantation: a prospective study. Transplant Proc. 2009;41:154–157.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner